The global AI in pharmacovigilance market is projected to grow from $0.77 billion in 2025 to $0.92 billion in 2026 and reach $1.88 billion by 2030, at a CAGR of 19.6%. Key drivers include rising adverse drug reaction reporting requirements, expanding regulations, and the growing use of electronic health records and complex clinical trial data. The Department of Health Abu Dhabi recorded 1,522 adverse drug reaction reports in 2023, a 235% increase over the average of previous years. RxLogix upgraded its PVOne.AI platform in May 2026 with agentic AI, and the company says it can cut manual case-processing effort by up to 80%. North America was the largest regional market in 2025, while Asia-Pacific is expected to grow fastest.
Summary written by Upside AI from the original article. Read the source for full details.
Read the original on Yahoo Finance ↗
Keywords
pharmaceuticalsartificial intelligencehealthcare
Open a keyword to see other news on the same topic.
Related tickers and likely impact
MSFT
• NeutralMicrosoft
Relevance: low
| Market | US stocks |
|---|---|
| Sector | Information Technology |
| Industry | Systems Software |
| Market cap | $3.9T |
| Close on 10/27/2026 | 531.60 |
| Change that session | -0.19% |
Impact is scored by AI from the headline and may be wrong. It is not investment advice.
Related news
- Artificial Intelligence (AI)-Driven Drug Safety and Pharmacovigilance Platforms Market Report 2026 | Capitalize on 20.2% CAGR with Microsoft, IBM, Oracle, IQVIA, and Veeva
The global AI-driven drug safety and pharmacovigilance platforms market is projected to grow from $2.14 billion in 2025 to $2.59 billion in 2026, a CAGR of 20.6%, and reach $5.39 billion by 2030, at a CAGR of 20.2%. Growth is driven by rising adverse drug reaction reporting requirements, stricter regulation, and wider use of real-world evidence and cloud-based monitoring systems. The Department of Health Abu Dhabi recorded 1,522 adverse drug reaction reports in 2023, a 235% increase over the average of previous years. RxLogix upgraded its PVOne.AI platform in May 2026 with agentic AI, which the company says can cut manual case-processing effort by up to 80%. North America was the largest regional market in 2025, while Asia-Pacific is expected to grow fastest.
- Why Is CVS Health (CVS) Hiring A Top AI Leader For Pharmacy?
CVS Health has appointed Jack Hanlon as senior vice president of AI and Analytics for its retail and pharmacy operations, after he held senior data and analytics roles at Meta and Reddit. The role focuses on applying advanced AI and analytics across CVS pharmacy, front-store activity and customer programs. The article says the hire reinforces the company's focus on technology and AI-driven cost savings, tied to a decade-long plan to spend more than US$20b on technology and more than US$1b in operating expense savings already linked to AI and automation in claims, prior authorization and pharmacy operations. It adds that the move will matter more if upcoming quarterly results and 2027 guidance show concrete operating metrics linked to AI, rather than only more talk about tools and platforms.
- Boehringer and Microsoft collaborate to explore AI in clinical research
Boehringer Ingelheim and Microsoft have launched a strategic collaboration to explore AI in clinical research, starting with lung health studies. The focus is on digital patient twins, computer-based models of individual patients built from clinical data, to test whether they can forecast disease progression and patient outcomes. The companies will assess whether these models can serve as synthetic or hybrid control arms, potentially reducing the number of participants in control groups, streamlining trial design and speeding up evidence generation. If successful, the approach could improve drug development efficiency and allow more trial participants to receive experimental treatments. The alliance also covers data centre modernisation and technical security, with further joint initiatives under review in animal health and commercial processes.
- Healthcare and Life Sciences Leaders Build on NVIDIA to Advance Drug Discovery and Expand Patient Care
NVIDIA and the UW Medicine Institute for Protein Design debuted RFD4-Proteina, an open model that combines programmable protein design with search capabilities so scientists and agents can refine designs using constraints and scoring objectives. In reported testing, it achieved higher computational design success rates and throughput than baselines across 4 benchmark suites. Siemens Healthineers is working with NVIDIA on next-generation adaptive radiotherapy using agentic co-planning, patient-specific simulation and robotic control. Automata, Benchling, Danaher and others are using the BioNeMo platform to build scientific agents that link drug design, autonomous labs and biological discovery. Projections show about 35 million people worldwide will be diagnosed with cancer each year by 2050.
- Rapid Micro Biosystems to Participate at the PDA Pharmaceutical Microbiology Conference 2026
Rapid Micro Biosystems (Nasdaq: RPID) said it will sponsor the PDA Pharmaceutical Microbiology Conference 2026 in Washington, D.C., October 26-28, and invites visitors to Booth 101. Its Growth Direct platform will be featured in a presentation by Sophia Pfeiffer of Boehringer Ingelheim on Monday, October 26 at 1:10 p.m. ET, covering early detection of mold contamination using computer vision and AI. The company describes Growth Direct as an industry-leading, fully automated, non-destructive, growth-based platform for microbial quality control testing.
- Billionaire Stanley Druckenmiller Added to Revolution Medicines Before Its FDA Win. Is the Stock Still a Buy After a 134% Run?
Duquesne Family Office, led by billionaire Stanley Druckenmiller, increased its Revolution Medicines stake by 26.5% in the second quarter, before the company's Rasonque won U.S. approval in August for certain pancreatic cancer patients. In a Phase 3 study, Rasonque achieved median overall survival of 13.2 months versus 6.7 months for chemotherapy, and some estimates project it could generate $15.1 billion in revenue by 2034 from pancreatic cancer alone. Some estimates put the number of U.S. patients diagnosed annually with metastatic pancreatic cancer at 55,000, with about 19,000 moving on to second-line treatment; assuming a roughly 30% net discount, the opportunity is nearly $3 billion a year. With a market cap of about $40 billion that has fallen since approval, the author says that at a 12% required rate of return and a forward price-to-sales ratio of 4 by 2031, revenue would need to reach $17.62 billion in 2032 to justify the current valuation. The author says they would seriously consider investing if the market cap falls by another $5 billion, citing clinical, regulatory and biotech volatility risks.
Related markets
Latest news
- Investing $1,000 in Each of These 3 Stocks 20 Years Ago Would Have Created a Portfolio Worth $674,000 Today
The article calculates that a $1,000 investment in each of Nvidia, Netflix and Amazon 20 years ago would be worth about $674,000 combined as of October 26. Nvidia's stake would be worth about $383,000, with most gains coming in the past couple of years as generative AI took off; the chipmaker's operating profit totaled nearly $200 billion over the past four quarters, its market cap is around $5.3 trillion, and it trades at 28 times trailing earnings. Netflix's stake would be worth more than $161,000, but its stock has fallen this year on concerns about slowing growth and is trading near its 52-week low. Amazon's stake would be worth about $130,000, and its operating income last year reached $80 billion, more than six times the $12 billion of three years earlier; the stock trades at around 20 times trailing earnings. The author argues these growth stocks can still be good buys today.
- Western Digital, Allegro MicroSystems, Amtech, and Teradyne shares skyrocket, what you need to know
Several semiconductor stocks rose sharply in the afternoon session after Broadcom obtained $63 billion in bank financing to develop proprietary AI chips for Anthropic. Alongside Anthropic's IPO filing and Meta's equity offering, the news signaled that tech capital spending remains robust. Among the gainers, Western Digital (WDC) rose 8.1%, Allegro MicroSystems (ALGM) gained 6.4%, Amtech (ASYS) added 5.1% and Teradyne (TER) climbed 5.6%. The article notes WDC has had 79 moves greater than 5% over the past year, and about 22 hours earlier the stock had gained 5.2% after Bank of America projected memory chip supplies would stay tight through 2028. Citing CNBC, the article says semiconductor fabrication equipment spending is projected to exceed $200 billion in 2027, as demand outpaces clean-room capacity and the availability of critical parts.
- Why Cerebras Systems Stock Jumped on Tuesday
Cerebras Systems (CBRS) shares rose sharply on Tuesday, climbing as much as 11.2% intraday and closing up 10.1%, after the company announced its fast inference service would be available to Oracle Cloud Infrastructure (OCI) customers. Cerebras says its Wafer-Scale Engine packs 900,000 compute cores and is 58 times larger than Nvidia's Blackwell B200 chip, and that integrating compute and memory on one wafer reduces latency, a key issue for AI agent workflows. In the second quarter, its cloud revenue surged 287% to a record $128 million and total revenue rose 103% to $210 million, though losses continue to mount as it expands data center capacity. The article notes the technology is still finding its customer base and that Cerebras competes directly with Nvidia. At 39 times sales, the article says its valuation reflects considerable growth expectations.
- Why Tech Giants Keep Laying Off Staff
On October 26, Microsoft said it is offering about 60,000 employees voluntary departure packages with severance, equal to more than 25% of its global workforce, as it seeks to cut costs and redirect funds to AI investment. Other companies have made big cuts this year, including Meta's 10% reduction (about 8,000 people) and Block's 40% cut (over 4,000 employees), and Layoffs.fyi counts more than 135,000 tech job cuts so far. The article says companies are prioritizing spending on AI chips and data centers and believe they can operate with fewer staff, although some reductions mainly correct earlier over-hiring. However, analysts warn that mass layoffs can hurt morale and push talented workers to leave, while humans are still needed to design business models, serve customers and ensure AI tools are used safely. The layoffs also reinforce fears that AI will destroy jobs, which could fuel opposition to data centers and the technology itself.
- JPM's Agather & Herbst on Texas Wealth Wave
Elaine Agather, Global Vice Chair of J.P. Morgan Private Bank and Dallas Region Chairman of JPMorgan Chase, and Ashley Herbst, Managing Director and Head of Dallas for J.P. Morgan Private Bank, speak with Bloomberg's Joe Lovinger about capital inflows, generational wealth transfer and Texas' changing investment landscape. The discussion takes place at Bloomberg Invest Dallas 2026.
- Why is Dell (DELL) stock soaring today
Dell shares jumped 8.3% in the afternoon session after the company expanded its cybersecurity and resilience portfolio for AI environments and introduced new AI-focused personal computers. The new services include Security Hardening for the Dell AI Factory, available this month, which reviews configuration risks across physical, virtual and application layers; Resilience Operations for AI, available now, which identifies critical AI applications and writes recovery plans; and PowerProtect identity tools that restore clean copies of Active Directory, Microsoft Entra ID and Okta after an attack. Earlier, the stock gained 6.3% after Super Micro Computer raised its revenue forecast to $18.5 billion to $19.5 billion, and Dell expanded its Dell AI Factory collaboration with NVIDIA at the GTC Berlin event, with over 6,500 organizations adopting the offerings. Dell is up 294% year to date, but at $503.78 it trades 14.4% below its 52-week high of $588.40 from September 2026.
Get the briefing on Telegram or Zalo
Join the Upside Telegram channel or Zalo group for the Vietnam stocks and gold briefing at 8:00 and 19:00 (Vietnam time) on trading days, plus a weekly wrap on Saturday morning.